Pfizer Inc. (NYSE: PFE) today announced that after a comprehensive internal and external selection process, the company is appointing Chris Boshoff, M.D., PhD, as Chief Scientific Officer and ...

MSD has reported positive topline outcomes from the Phase III study of subcutaneous pembrolizumab in conjunction with ...

The phase 3 MK-3475A-D77 trial tested subcutaneous and intravenous Keytruda given every six weeks in combination with ...

Already a subscriber? Click the image to view the latest e-edition.

Merck & Co. Inc.'s reported positive results Tuesday for a new, easier-to-administer formulation of its blockbuster cancer drug Keytruda. Rahway, N.J.-based Merck (MRK) said a trial of the drug, given ...

Merck's (MRK) new injectable version of Keytruda aims to overcome regulatory hurdles and market challenges, offering a more ...

Merck (MRK) announced positive topline results from the pivotal Phase 3 MK-3475A-D77 trial. The trial is evaluating the noninferiority of ...

Merck (MRK) stock gains as its subcutaneously delivered pembrolizumab meets key goals in Phase 3 trial against intravenous ...

Committee for Medicinal Products for Human Use (CHMP) has rendered a positive opinion, recommending the approval of its ...

At age 20, while studying sports management and marketing in college, Sean Kukoleck's life was disrupted by cancer. He suffered his first-ever seizure, leading to the discovery of a large mass on ...

Q3 2024 Earnings Call Transcript November 14, 2024 Operator: Good morning ladies and gentlemen and welcome to PDS Biotech’s Third Quarter 2024 Results and Clinical Strategy Update Conference Call. All ...

Treatment with the anti-TIGIT antibody vibostolimab and Keytruda (pembrolizumab) plus etoposide and platinum did not improve ...